Objectives: In clinical trials elexacaftor/tezacaftor/ivacaftor (ETI) has shown significant improvement in clinically important parameters in children with CF (cwCF) including reduction in sweat chloride levels. In our study we aimed to check effect of ETI on sweat chloride levels in cwCF in real-world clinical practice.